全部照片(1)

文件

來源證明/COA

311-500

Smooth Muscle Cell Growth Medium (500 ml)

Name: Smooth Muscle Cell Growth Medium (500 ml)
Brand: SIGMA

同義詞:

Primary Cell Culture Media

登入查看組織和合約定價

全部照片(1)

About This Item

分類程式碼代碼:

12352207

NACRES:

NA.71

推薦產品

Slide 1 of 9

1 of 9

Sigma-Aldrich

310-500

Smooth Muscle Cell Basal Medium (500 ml)

Sigma-Aldrich

311-GS

Smooth Muscle Cell Growth Supplement (30 ml)

Sigma-Aldrich

311D-250

Smooth Muscle Cell Differentiation Medium (250 ml)

Sigma-Aldrich

354-05A

Human Aortic Smooth Muscle Cells: HAOSMC, adult

Sigma-Aldrich

B354-05

Bovine Aortic Smooth Muscle Cells: BAOSMC (Cryovial)

Sigma-Aldrich

T3924

胰蛋白酶-EDTA 溶液

Sigma-Aldrich

R2625

视黄酸

Sigma-Aldrich

SCC065

HL-1 心肌细胞系

Sigma-Aldrich

150-05A

人骨骼肌细胞：HSkMC ，成人

形狀

liquid

品質等級

100

儲存期限

6 mo.

製造商／商標名

Cell Applications, Inc

運輸包裝

wet ice

儲存溫度

2-8°C

一般說明

All-in-one ready-to-use media

應用

Smooth Muscle Cell Growth Medium (500 ml) has been used in culturing of human smooth muscle cells.

品質

Each lot was tested for the ability to support plating, spreading and proliferation

準備報告

contained in protocol

儲存類別代碼

12 - Non Combustible Liquids

水污染物質分類（WGK）

WGK 1

閃點（°F）

Not applicable

閃點（°C）

Not applicable

分析證明 (COA)

輸入產品批次/批號來搜索分析證明 (COA)。在產品’s標籤上找到批次和批號，寫有 ‘Lot’或‘Batch’.。

已經擁有該產品？

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

客戶也查看了

Slide 1 of 4

1 of 4

Sigma-Aldrich

3514-05A

Human Carotid Artery Smooth Muscle Cells: HCtASMC, adult

Sigma-Aldrich

724459

羧酸封端的聚(N-异丙基丙烯酰胺)

Sigma-Aldrich

300-05A

Human Coronary Artery Endothelial Cells: HCAEC, adult

Sigma-Aldrich

212-500

MesoEndo Cell Growth Medium (500 ml)

A cautionary tale for autologous vascular tissue engineering: impact of human demographics on the ability of adipose-derived mesenchymal stem cells to recruit and differentiate into smooth muscle cells.

Jeffrey T Krawiec et al.

Tissue engineering. Part A, 21(3-4), 426-437 (2014-08-15)

Autologous tissue-engineered blood vessels (TEBVs) generated using adult stem cells have shown promising results, but many preclinical evaluations do not test the efficacy of stem cells from patient populations likely to need therapy (i.e., elderly and diabetic humans). Two critical